Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven I&g 4 Regulatory News (MAV4)

Share Price Information for Maven I&g 4 (MAV4)

Share Price is delayed by 15 minutes
Get Live Data
50.00    0.00 (0.00%)
Bid:
49.00
Ask:
51.00
Spread: 2.00 (4.082%)
Market Cap: £83.71m
MAV4 Live PriceLast checked at - London Stock Exchange

Intraday Maven I&g 4 Share Chart

Interim Management Statement - Amendment

16 Nov 2009 12:04

RNS Number : 5579C
Aberdeen Grwth Opp VCT2 PLC
16 November 2009
 



Aberdeen Growth Opportunities VCT PLC 

Correction to Interim Management Statement 

This is a correction to the previous announcement of the Interim Management Statement, which contained an error in the last line. The corrected Interim Management Statement is set out below:

1. Net Asset Value

Ordinary share net asset value (NAV) of 89.5p at 30 September 2009

S Ordinary share net asset value (NAV) of 94.2p at 30 September 2009 

The NAVs shown above are unaudited and reflect the closing bid prices of quoted securities at 30 September 2009. Unlisted companies are normally valued on a six-monthly basis and the NAVs include the Directors' valuations of unlisted investments as at 30 June 2009 adjusted for material developments within the portfolios since that date.  

2. Investments and disposals

During the quarter ended 30 September 2009the Ordinary share portfolio invested £37,000 in Adler and Allan. During the same period, disposals generated aggregate proceeds of £473,613 against cost of £457,820.

The S share portfolio invested £19,000 in the same company and during the same period, generated aggregate disposals proceeds of £165,324 against cost of £145,250.

There were no other material transactions during the period under review. 

3. Recent developments 

No further investments have been made between 30 September 2009 and the date of this statement. Since 30 September 2009, the investment in Cyclotech has been sold, realising proceeds of £688,000 and £275,000 for the Ordinary and S ordinary portfolios, compared with costs of £248,661 and £99,464 respectively. During that period, further disposals generated proceeds of £18,331 for each of the Ordinary share portfolio and the S share portfolio against similar costs.

The Board is not aware of any other events or transactions that have taken place between 30 September 2009 and the date of publication of this statement and which would have had a material impact on the financial position of the Company. 

Issued on behalf of the Board

Maven Capital Partners UK LLP, Secretary

16 November 2009

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSBFBBTMMBBBLL
Date   Source Headline
20th May 202610:12 amRNSAdmission of Further Securities to Trading
15th May 202610:45 amRNSDirector/PDMR Shareholding
15th May 202610:41 amRNSIssue of Equity - Dividend Investment Scheme
14th May 20265:22 pmRNSTransaction in Own Shares
12th May 20263:37 pmRNSUnaudited NAV - Dividend Investment Scheme
7th May 20261:45 pmRNSResult of AGM
30th Apr 202610:58 amRNSAdmission of Further Securities to Trading
29th Apr 202612:29 pmRNSIssue of Equity
20th Apr 202612:23 pmRNSPublication of a Supplementary Prospectus
15th Apr 202611:27 amRNSAdmission of Further Securities to Trading
14th Apr 202611:09 amRNSIssue of Equity
10th Apr 202612:02 pmRNSUnaudited Net Asset Value
8th Apr 20269:33 amRNSAdmission of Further Securities to Trading
25th Mar 20263:51 pmRNSTransaction in Own Shares
25th Mar 202610:55 amRNSAdmission of Further Securities to Trading
24th Mar 202612:11 pmRNSIssue of Equity
19th Mar 20264:21 pmRNSUnaudited NAV and Proposed Final Dividend
18th Feb 20264:58 pmRNSAdmission of Further Securities to Trading
17th Feb 202611:07 amRNSDirector/PDMR Shareholding
17th Feb 202611:07 amRNSDirector/PDMR Shareholding
17th Feb 202610:54 amRNSIssue of Equity
4th Feb 20267:00 amRNSStatement re Offer for Subscription
21st Jan 202611:07 amRNSAdmission of Further Securities to Trading
20th Jan 20262:05 pmRNSAdmission of Further Securities to Trading
16th Jan 20269:52 amRNSDirector/PDMR Shareholding
16th Jan 20269:44 amRNSIssue of Equity
15th Jan 202610:36 amRNSDirector/PDMR Shareholding
15th Jan 202610:35 amRNSDirector/PDMR Shareholding
15th Jan 20269:55 amRNSIssue of Equity
14th Jan 20262:39 pmRNSUnaudited NAV - Dividend Investment Scheme
13th Jan 202612:10 pmRNSUnaudited Net Asset Value
4th Dec 202510:35 amRNSSecond Interim Dividend
18th Nov 20253:48 pmRNSTransaction in Own Shares
14th Nov 20259:31 amRNSNet Asset Value(s)
13th Nov 20254:53 pmRNSResult of General Meeting
2nd Oct 20254:42 pmRNSPublication of a Prospectus
29th Aug 20257:00 amRNSDirector/PDMR Shareholding
29th Aug 20257:00 amRNSIssue of Equity
29th Aug 20257:00 amRNSHalf-year Report
20th Aug 20252:14 pmRNSStatement re Dividend Investment Scheme
31st Jul 20254:42 pmRNSTransaction in Own Shares
16th Jul 202510:18 amRNSStatement re Unaudited NAV and Interim Dividend
16th Jul 20257:08 amRNSStatement re Offer for Subscription
21st May 20254:44 pmRNSTransaction in Own Shares
16th May 20259:30 amRNSDirector/PDMR Shareholding
16th May 20259:26 amRNSIssue of Equity - Dividend Investment Scheme
9th May 20251:53 pmRNSStatement re Dividend Investment Scheme
9th May 202510:03 amRNSNet Asset Value(s)
8th May 20251:43 pmRNSResult of AGM
6th May 202511:55 amRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.